Figure 6

Anti-tumor activity of bevacizumab and radiation given concurrently in SCC1 and H226 xenograft models. Four groups of mice with SCC1 and H226 tumors were treated with: IgG (control), bevacizumab (B), radiation (X), and concurrent bevacizumab and radiation (B/X). (A) Treatment schedule, and tumor growth inhibition in (B) SCC1 and (C) H226 models (n = 8 tumors per treatment group for each cell line).